LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

Search

Celldex Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

24.57 0.24

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

24.37

Max

24.99

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-2.8M

-57M

Pardavimai

35K

730K

Pelno marža

-7,753.425

Darbuotojai

186

EBITDA

-1.1M

-63M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+113.8% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-04

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

180M

1.6B

Ankstesnė atidarymo kaina

24.33

Ankstesnė uždarymo kaina

24.57

Naujienos nuotaikos

By Acuity

21%

79%

48 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-09-16 17:03; UTC

Pagrindinės rinkos jėgos

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

2025-09-16 16:49; UTC

Pagrindinės rinkos jėgos
Įsigijimai, susijungimai, perėmimai

GD Culture Shares Drop After Deal for Pallas Capital

2025-09-16 16:11; UTC

Pagrindinės rinkos jėgos

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

2025-09-16 23:40; UTC

Rinkos pokalbiai

Nikkei May Decline as Yen Strengthens -- Market Talk

2025-09-16 23:34; UTC

Rinkos pokalbiai

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

2025-09-16 23:20; UTC

Rinkos pokalbiai

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

2025-09-16 21:10; UTC

Įsigijimai, susijungimai, perėmimai

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

2025-09-16 20:51; UTC

Rinkos pokalbiai

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

2025-09-16 20:50; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2025-09-16 20:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2025-09-16 20:25; UTC

Uždarbis

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

2025-09-16 20:24; UTC

Uždarbis

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

2025-09-16 19:19; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

2025-09-16 18:52; UTC

Rinkos pokalbiai

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

2025-09-16 18:44; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-09-16 18:44; UTC

Rinkos pokalbiai

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

2025-09-16 18:40; UTC

Įsigijimai, susijungimai, perėmimai

Details Emerge on U.S.-China TikTok Deal -- WSJ

2025-09-16 18:38; UTC

Rinkos pokalbiai

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

2025-09-16 18:19; UTC

Rinkos pokalbiai

Gold Settles at New High Ahead of Fed Decision -- Market Talk

2025-09-16 18:01; UTC

Rinkos pokalbiai

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

2025-09-16 17:34; UTC

Rinkos pokalbiai

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

2025-09-16 16:53; UTC

Uždarbis

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

2025-09-16 16:20; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2025-09-16 16:15; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Global Commodities Roundup: Market Talk

2025-09-16 16:09; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Global Energy Roundup: Market Talk

2025-09-16 16:09; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

2025-09-16 15:35; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-16 15:35; UTC

Rinkos pokalbiai

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

2025-09-16 15:22; UTC

Rinkos pokalbiai

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

2025-09-16 15:21; UTC

Rinkos pokalbiai

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

113.8% į viršų

12 mėnesių prognozė

Vidutinis 52.38 USD  113.8%

Aukščiausias 67 USD

Žemiausias 38 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

10

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

48 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat